Naureen Quibria
Stock Analyst at Capital One
(0.14)
# 4,100
Out of 4,721 analysts
11
Total ratings
18.18%
Success rate
-38.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $3.92 | +537.76% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $2.14 | +367.29% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $2.67 | +199.63% | 1 | Mar 11, 2024 | |
| CARM Carisma Therapeutics | Initiates: Overweight | $10 | $0.55 | +1,718.18% | 1 | Oct 3, 2023 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $29.87 | +181.22% | 1 | Aug 16, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $12.20 | +227.87% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $6.08 | +80.92% | 1 | Sep 7, 2022 | |
| CMRX Chimerix | Initiates: Overweight | $7 | $3.54 | +97.74% | 2 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $4.63 | +353.56% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $180 | $1.80 | +9,900.00% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $3.92
Upside: +537.76%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $2.14
Upside: +367.29%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $2.67
Upside: +199.63%
Carisma Therapeutics
Oct 3, 2023
Initiates: Overweight
Price Target: $10
Current: $0.55
Upside: +1,718.18%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $29.87
Upside: +181.22%
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $12.20
Upside: +227.87%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $6.08
Upside: +80.92%
Chimerix
Sep 7, 2022
Initiates: Overweight
Price Target: $7
Current: $3.54
Upside: +97.74%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $4.63
Upside: +353.56%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $180
Current: $1.80
Upside: +9,900.00%